INTRODUCTION: The 12-gene colon cancer Recurrence Score assay is a clinically validated predictor of recurrence risk in stage II colon cancer patients. A survey was performed characterizing the assay's impact on treatment recommendations for these patients. METHODS: US medical oncologists (n = 346) who ordered the assay for ≥3 stage II colon cancer patients were asked to complete a web-based survey regarding their most recent such patient. Physicians surveyed represented users of the assay within the first 2 years of commercial availability which may include 'early adopters'. RESULTS: Most of 116 eligible physicians were in community practice (86%), with median 14.5 years' experience (range = 2-40). Mean patient age was 61 years (range = 32-85); 81% had T3 disease, and 38% had comorbidities. Of 76 patients tested for mismatch-repair/microsatellite-instability (MMR/MSI), 13 (17%) were MMR-deficient/MSI-high; 46 (61%) MMR-proficient/MSI-low; and 17 (22%) unknown. Most patients (84%) had ≥12 nodes examined. Median Recurrence Score result was 20 (range = 1-77). Before assay, treatment recommendations were specified for 92 (79%) patients, with no recommendation for 24 (21%). Of the 92 with pre-assay recommendations, chemotherapy was planned for 52 (57%) and observation for 40 (43%); the assay changed recommendations for 27 (29%). Treatment intensity decreased for 18 (67%) and increased for nine (33%) patients; it was more likely to decrease for lower Recurrence Score values and increase for higher values (p < 0.001). CONCLUSION: For stage II colon cancer patients receiving Recurrence Score testing, 29% of treatment recommendations were changed. Use of the assay may lead to reductions in treatment intensity. Study limitations include retrospective design, data gathering during the first 2 years of assay availability only, and potential non-representativeness of respondents.
INTRODUCTION: The 12-gene colon cancer Recurrence Score assay is a clinically validated predictor of recurrence risk in stage II colon cancerpatients. A survey was performed characterizing the assay's impact on treatment recommendations for these patients. METHODS: US medical oncologists (n = 346) who ordered the assay for ≥3 stage II colon cancerpatients were asked to complete a web-based survey regarding their most recent such patient. Physicians surveyed represented users of the assay within the first 2 years of commercial availability which may include 'early adopters'. RESULTS: Most of 116 eligible physicians were in community practice (86%), with median 14.5 years' experience (range = 2-40). Mean patient age was 61 years (range = 32-85); 81% had T3 disease, and 38% had comorbidities. Of 76 patients tested for mismatch-repair/microsatellite-instability (MMR/MSI), 13 (17%) were MMR-deficient/MSI-high; 46 (61%) MMR-proficient/MSI-low; and 17 (22%) unknown. Most patients (84%) had ≥12 nodes examined. Median Recurrence Score result was 20 (range = 1-77). Before assay, treatment recommendations were specified for 92 (79%) patients, with no recommendation for 24 (21%). Of the 92 with pre-assay recommendations, chemotherapy was planned for 52 (57%) and observation for 40 (43%); the assay changed recommendations for 27 (29%). Treatment intensity decreased for 18 (67%) and increased for nine (33%) patients; it was more likely to decrease for lower Recurrence Score values and increase for higher values (p < 0.001). CONCLUSION: For stage II colon cancerpatients receiving Recurrence Score testing, 29% of treatment recommendations were changed. Use of the assay may lead to reductions in treatment intensity. Study limitations include retrospective design, data gathering during the first 2 years of assay availability only, and potential non-representativeness of respondents.
Authors: Benjamin G Allar; Evangelos Messaris; Vitaliy Y Poylin; Benjamin L Schlechter; Thomas E Cataldo Journal: Med Oncol Date: 2022-02-12 Impact factor: 3.064
Authors: Jennifer B Manders; Henry M Kuerer; Benjamin D Smith; Cornelia McCluskey; William B Farrar; Thomas G Frazier; Linna Li; Charles E Leonard; Dennis L Carter; Sheema Chawla; Lori E Medeiros; J Michael Guenther; Lauren E Castellini; Daniel J Buchholz; Eleftherios P Mamounas; Irene L Wapnir; Kathleen C Horst; Anees Chagpar; Suzanne B Evans; Adam I Riker; Faisal S Vali; Lawrence J Solin; Lisa Jablon; Abram Recht; Ranjna Sharma; Ruixiao Lu; Amy P Sing; E Shelley Hwang; Julia White Journal: Ann Surg Oncol Date: 2016-10-04 Impact factor: 5.344
Authors: W L Allen; P D Dunne; S McDade; E Scanlon; M Loughrey; H Coleman; C McCann; K McLaughlin; Z Nemeth; N Syed; P Jithesh; K Arthur; R Wilson; V Coyle; D McArt; G I Murray; L Samuel; P Nuciforo; J Jimenez; G Argiles; R Dienstmann; J Tabernero; L Messerini; S Nobili; E Mini; K Sheahan; E Ryan; P G Johnston; S Van Schaeybroeck; M Lawler; D B Longley Journal: JCO Precis Oncol Date: 2018-06-13